The Technical Analyst
Agios Pharmaceuticals Inc [AGIO]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Agios Pharmaceuticals Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
2.30% $30.21
America/New_York / 22 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 679.10 mill |
| EPS: | -3.92 |
| P/E: | -7.71 |
| Earnings Date: | Oct 18, 2023 |
| SharesOutstanding: | 55.58 mill |
| Avg Daily Volume: | 0.744 mill |
| RATING 2024-04-22 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -7.71 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -1.31x |
| Company: PE -7.71 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-8.44 (-127.93%) $-38.65 |
| Date: 2024-04-23 |
| Expected Trading Range (DAY) |
|---|
|
$ 29.10 - 31.32 ( +/- 3.66%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-08 | Fouse Jacqualyn A | Buy | 15 934 | Common stock |
| 2024-04-10 | Fouse Jacqualyn A | Sell | 7 791 | Common stock |
| 2024-04-08 | Fouse Jacqualyn A | Sell | 15 934 | Restricted stock units |
| 2024-03-07 | Foster-cheek Kaye I | Sell | 1 285 | Common stock |
| 2024-03-05 | Foster-cheek Kaye I | Sell | 300 | Common stock |
| INSIDER POWER |
|---|
| 24.98 |
| Last 100 transactions |
| Buy: 882 792 | Sell: 538 174 |
Forecast:
16:00 - $30.21
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $30.21
Forecast 2: 16:00 - $30.21
Forecast 3: 16:00 - $30.21
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $30.21 (2.30% ) |
| Volume | 0.824 mill |
| Avg. Vol. | 0.744 mill |
| % of Avg. Vol | 110.72 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For AGIO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $23.96 | N/A | Active |
|---|
AGIO
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Last 10 Buy Signals
Latest Press Releases
2024-04-18 07:00:00 - Press Release
Agios To Webcast Conference Call Of First Quarter 2024 Financial Results On May 2, 2024
Cambridge, mass., april 18, 2024 (globe newswire) -- agios pharmaceuticals, inc. (nasdaq: agio), a leader in cellular metabolism and pk activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on thursday, may 2, 2024, at 8:00 a.m. et to report its first quarter 2024 financial results and other business highlights.
2024-03-05 07:00:00 - Press Release
Agios To Present At The Leerink Partners Global Biopharma Conference on March 12, 2024
Cambridge, mass., march 05, 2024 (globe newswire) -- agios pharmaceuticals, inc. (nasdaq: agio), a leader in cellular metabolism and pk activation pioneering therapies for rare diseases, today announced that the company is scheduled to present at the leerink partners global biopharma conference on tuesday, march 12, 2024, at 10:00 a.m.
2024-02-22 07:00:00 - Press Release
Agios To Present At The Td Cowen 44th Annual Health Care Conference On March 4, 2024
Cambridge, mass., feb. 22, 2024 (globe newswire) -- agios pharmaceuticals, inc. (nasdaq: agio), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that the company is scheduled to present at the td cowen 44th annual health care conference on monday, march 4, 2024, at 2:10 p.m.
2024-02-15 07:00:00 - Press Release
Agios Reports Fourth Quarter And Full Year 2023 Financial Results And Recent Business Highlights
– announced positive results from the phase 3 energize study of mitapivat in adults with non-transfusion-dependent alpha- or beta-thalassemia – – presented positive results from phase 2 portion of the rise up pivotal study in sickle cell disease at 65th ash annual meeting and exposition – – two additional phase 3 readouts of mitapivat expected in 2024, with a total of four phase 3 readouts by the end of 2025 – – u.s. pyrukynd ® (mitapivat) net revenue of $7.1 million in q4; cash, cash equivalents and marketable securities of $806.4 million as of december 31, 2023 – cambridge, mass., feb. 15, 2024 (globe newswire) -- agios pharmaceuticals, inc. (nasdaq: agio), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today reported business highlights and financial results for the fourth quarter and year ended december 31, 2023.
2024-02-02 07:00:00 - Press Release
Agios To Webcast Conference Call Of Fourth Quarter And Year End 2023 Financial Results On February 15, 2024
Cambridge, mass., feb. 02, 2024 (globe newswire) -- agios pharmaceuticals, inc. (nasdaq: agio), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on thursday, february 15, 2024, at 8:00 a.m. et to report its fourth quarter and year end 2023 financial results and other business highlights.
Latest News
2024-03-05 07:00:00 - GlobeNewsWire
Agios to Present at the Leerink Partners Global Biopharma Conference on March 12, 2024
CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that the company is scheduled to present at the Leerink Partners Global Biopharma Conference on Tuesday, March 12, 2024, at 10:00 a.m.
2024-02-22 07:00:00 - GlobeNewsWire
Agios to Present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024
CAMBRIDGE, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that the company is scheduled to present at the TD Cowen 44th Annual Health Care Conference on Monday, March 4, 2024, at 2:10 p.m.
2024-02-16 10:41:14 - Zacks Investment Research
Agios (AGIO) Q4 Earnings & Revenues Fall Short of Estimates
Agios' (AGIO) earnings and revenues miss estimates in the fourth quarter of 2023. Revenues from its sole marketed drug, Pyrukynd, rise year over year.
2024-02-15 14:08:04 - Seeking Alpha
Agios Pharmaceuticals (AGIO) Q4 2023 Earnings Call Transcript
2024-02-15 09:26:03 - Zacks Investment Research
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Misses Revenue Estimates
Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.72 per share versus the Zacks Consensus Estimate of a loss of $1.64. This compares to earnings of $0.67 per share a year ago.
2024-02-08 16:10:42 - InvestorPlace
7 Biotech Stocks Fighting America's Deadliest Diseases
Unlike many other market segments, biotech stocks stand out for their direct relevance. For example, investors who typically wager on aerospace and defense plays usually aren't fighter pilots.
2024-02-08 11:05:54 - Zacks Investment Research
Earnings Preview: Agios Pharmaceuticals (AGIO) Q4 Earnings Expected to Decline
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2024-02-02 07:00:00 - GlobeNewsWire
Agios to Webcast Conference Call of Fourth Quarter and Year End 2023 Financial Results on February 15, 2024
CAMBRIDGE, Mass., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, February 15, 2024, at 8:00 a.m. ET to report its fourth quarter and year end 2023 financial results and other business highlights.
2024-01-04 12:47:38 - Zacks Investment Research
Agios (AGIO) Up 5% on Upbeat Data From Thalassemia Study
Data from a late-stage study shows that non-transfusion-dependent thalassemia patients who received Agios' (AGIO) mitapivat demonstrated a statistically significant increase in hemoglobin response.
2024-01-04 09:02:15 - Zacks Investment Research
Agios Pharmaceuticals (AGIO) Soars 5.2%: Is Further Upside Left in the Stock?
Agios Pharmaceuticals (AGIO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.